DMB-I in the Treatment of Alzheimer Type Dementia

Summary

The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.

Timeline

Start

2023-12-27

Primary completion

2025-01-13

Completion

2025-01-31

Publications

• Gorin BI, Pozdnyakov SO, Potapova KA, Tukhovskaya EA, Gorchakov DS. Efficacy and safety of DMB-I (latrepirdine) therapy in mild to moderate dementia in Alzheimer's disease: results of a multicenter, double-blind, randomized, placebo-controlled, clinical trial in three parallel groups. Sci Rep. 2026 May 15;16(1):14027. doi: 10.1038/s41598-026-49538-4.

Drugs

Indications